# ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

> clinical trial · VERIFIED · 2026-07-23

Status: NOT_YET_RECRUITING · Sponsor: University of Wisconsin, Madison · Condition: Merkel Cell Carcinoma

- Company: University of Wisconsin, Madison
- Sector: Merkel Cell Carcinoma
- Primary source: https://clinicaltrials.gov/study/NCT07472322

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.